[{"address1": "Ugland House", "address2": "PO Box 309", "city": "Grand Cayman", "zip": "KY1-1104", "country": "Cayman Islands", "phone": "848 230 7430", "website": "https://www.adlainortye.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.", "fullTimeEmployees": 123, "companyOfficers": [{"maxAge": 1, "name": "Mr. Yang  Lu", "age": 43, "title": "Co- Founder, CEO & Chairman", "yearBorn": 1981, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kaiyang  Tang", "age": 59, "title": "President", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Xiaofeng  Ye Ph.D.", "age": 45, "title": "Interim CFO and VP of Business Development & Commercialization Strategy", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ngai Chiu  Tse M.D., Ph.D.", "age": 57, "title": "Head of Research & Development", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.3899, "open": 1.43, "dayLow": 1.36, "dayHigh": 1.59, "regularMarketPreviousClose": 1.3899, "regularMarketOpen": 1.43, "regularMarketDayLow": 1.36, "regularMarketDayHigh": 1.59, "payoutRatio": 0.0, "beta": -0.876, "forwardPE": -0.882716, "volume": 26160, "regularMarketVolume": 26160, "averageVolume": 9885, "averageVolume10days": 10740, "averageDailyVolume10Day": 10740, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 52767380, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 3.89, "allTimeHigh": 19.3, "allTimeLow": 1.1, "priceToSalesTrailing12Months": 27.19968, "fiftyDayAverage": 1.69174, "twoHundredDayAverage": 1.824195, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 124369144, "profitMargins": 0.0, "floatShares": 66714945, "sharesOutstanding": 31236934, "sharesShort": 2038, "sharesShortPriorMonth": 1283, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0001, "heldPercentInsiders": 0.0859, "heldPercentInstitutions": 0.00191, "shortRatio": 0.21, "shortPercentOfFloat": 0.0001, "impliedSharesOutstanding": 36900300, "bookValue": 0.691, "priceToBook": 2.0694644, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -51869000, "trailingEps": -1.62, "forwardEps": -1.62, "enterpriseToRevenue": 64.108, "enterpriseToEbitda": -2.395, "52WeekChange": -0.2955665, "SandP52WeekChange": 0.19736934, "quoteType": "EQUITY", "currentPrice": 1.43, "recommendationKey": "none", "totalCash": 61159000, "totalCashPerShare": 0.552, "ebitda": -51924000, "totalDebt": 27226000, "quickRatio": 1.349, "currentRatio": 1.412, "totalRevenue": 1940000, "debtToEquity": 106.831, "revenuePerShare": 0.061, "returnOnAssets": -0.32840002, "returnOnEquity": -1.0319, "grossProfits": 1940000, "freeCashflow": -30614000, "operatingCashflow": -51819000, "revenueGrowth": 1.18, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -12.208759, "financialCurrency": "USD", "symbol": "ANL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Adlai Nortye Ltd.", "longName": "Adlai Nortye Ltd.", "regularMarketChange": 0.0401, "regularMarketDayRange": "1.36 - 1.59", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 9885, "fiftyTwoWeekLowChange": 0.32999992, "fiftyTwoWeekLowChangePercent": 0.29999992, "fiftyTwoWeekRange": "1.1 - 3.89", "fiftyTwoWeekHighChange": -2.46, "fiftyTwoWeekHighChangePercent": -0.63239074, "fiftyTwoWeekChangePercent": -29.55665, "marketState": "CLOSED", "corporateActions": [], "regularMarketTime": 1761940802, "exchange": "NGM", "messageBoardId": "finmb_1830112145", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.8851, "regularMarketPrice": 1.43, "earningsTimestampStart": 1754650740, "earningsTimestampEnd": 1755864000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.62, "epsForward": -1.62, "epsCurrentYear": -0.36, "priceEpsCurrentYear": -3.9722219, "fiftyDayAverageChange": -0.2617401, "fiftyDayAverageChangePercent": -0.15471649, "twoHundredDayAverageChange": -0.39419508, "twoHundredDayAverageChangePercent": -0.21609262, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-09-29", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1695994200000, "displayName": "Adlai Nortye", "trailingPegRatio": null, "__fetch_time": "2025-11-01"}]